Journal of Molecular Biomarkers and Clinical Trials
Ambulatory Arterial Stiffness Index (AASI) and Antihypertensive Drug Effects: A Study with Spironolactone
*Dr. Mario Bendersky Department Of Pharmacology, Córdoba University, Córdoba, Argentina
*Corresponding Author: Dr. Mario Bendersky
Department Of Pharmacology, Córdoba University, Córdoba, Argentina Email:firstname.lastname@example.org
Published on: 2016-08-31
Patients with essential hypertension have shown increased arterial stiffness. ABPM allows us to obtain AASI (Ambulatory Arterial Stiffness Index) through a mathematical formula (1-slope DBP/SBP) This index has many physiologic components (one of them is arterial stiffness), correlates well with Pulse Wave Velocity (PWV),and shows good prognostic value in normal and hypertensive populations: with increased AASI values, worse CV prognosis.
Ambulatory Arterial Stiffness Index, Antihypertensive Drug Effects, Spironolactone
163 patients with essential hypertension were included. Patients were classified as stage 1 (ESH 2007), with Aldosterone: Renin Score <20, they were on Enalapril 10 mg at least 30 days, nor receiving any other concomitant pharmacological agent capable of inducing changes in arterial stiffness, and did not undergo any lifestyle changes in the last month. All patients had ambulatory day BP greater than 135 and/or 85 mmHg (SBP and DBP). Mean age was 56.6 (54-65) years old, 63 patients were male, and BMI was 27.4 (25-29). We added Spironolactone 50 mg/d in morning dose for 3 months. AASI: 1-slope DBP/SBP[14-17].